JAK1 inhibitors(Tyrosine-protein kinase JAK1 inhibitors), JAK2 inhibitors(Tyrosine-protein kinase JAK2 inhibitors), STAT1 inhibitors(Signal transducer and activator of transcription 1-alpha/beta inhibitors)

Therapeutic Areas

Skin and Musculoskeletal DiseasesOther DiseasesNeoplasms+ [2]

Active Indication

Nonsegmental vitiligoPolycythemia VeraAcute Myeloid Leukemia+ [11]

Inactive Indication

Chronic Myelomonocytic Leukemiaprurigo nodularisPruritus

Originator Organization

Apotex, Inc.

Active Organization

Constellation Pharmaceuticals, Inc.

Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd.

Beijing Novartis Pharma Co., Ltd.

+ [3]

Inactive Organization

Novartis Pharmaceuticals Corp.Novartis Farmacéutica SANovartis Pharma GmbH

License Organization

Incyte Corp.Incyte Biosciences International SARLSpecialised Therapeutics Australia Pty Ltd.

Drug Highest PhasePhase 3

First Approval Date-

Regulation-

Structure/Sequence

Molecular FormulaC17H18N6

InChIKeyHFNKQEVNSGCOJV-OAHLLOKOSA-N

CAS Registry941678-49-5

139

Clinical Trials associated with Ruxolitinib

NCT07734077

/ Not yet recruitingPhase 1/2IIT

Phase Ib/II Study Of Revumenib As Monotherapy Or In Combination With Jak Inhibitors In Patients With Myelofibrosis

This is a Phase Ib/II 2 study investigating the safety and efficacy of revumenib in two cohorts of participants with myelofibrosis. COHORT-1 will investigate the safety of revumenib as monotherapy in participants with myelofibrosis previously treated with a JAK inhibitor. Following confirmation of safety in COHORT-1, the study will proceed with enrollment in COHORT-2, which will evaluate the efficacy and safety of revumenib in combination with a JAK inhibitor.

Start Date01 Dec 2026

Sponsor / Collaborator

Icahn School of Medicine at Mount Sinai

[+2]

NCT07661979

/ Not yet recruitingPhase 4IIT

Opzelura Experience Study

Atopic dermatitis is a common multifactorial skin disease. Topicals are the mainstay of treatment, but adherence to topicals is often abysmal, possibly worsened by the complexity of recommended treatment algorithms. Giving patients a simple, one drug approach may be advantageous.

Start Date01 Dec 2026

Sponsor / Collaborator

Wake Forest School of Medicine

NCT07498205

/ Not yet recruitingPhase 4IIT

A Randomized Open Label Trial Comparing Momelotinib vs Dose-Adjusted Ruxolitinib For Treatment-Naive, Cytopenic Myelofibrosis

The purpose of this study is to compare momelotinib and ruxolitinib as treatments for myelofibrosis with low blood cell counts. Both drugs are approved by the FDA to treat myelofibrosis. The study asks which drug does a better job at shrinking the spleen.

Start Date01 Nov 2026

Sponsor / Collaborator

SWOG

[+1]

100 Clinical Results associated with Ruxolitinib

100 Translational Medicine associated with Ruxolitinib

100 Patents (Medical) associated with Ruxolitinib

4,033

Literatures (Medical) associated with Ruxolitinib

31 Dec 2026·JOURNAL OF DERMATOLOGICAL TREATMENT

Management of adult vitiligo: approved topical JAK inhibitor and standard therapies

Review

Author: Perrotta, Nicola ; Cantisani, Carmen ; Greco, Maria Elisabetta ; Proietti, Ilaria ; Caro, Alberto di ; Sasso, Francesca Paola ; di Guardo, Antonio ; Potenza, Concetta ; Pellacani, Giovanni ; Fiorito, Luigi Angelo ; Feresin, Francesca ; Nisticò, Steven Paul ; Dattola, Annunziata

INTRODUCTION:

Vitiligo is a chronic autoimmune depigmenting disorder. Ruxolitinib 1.5% cream is currently the only therapy specifically approved for its treatment. In addition, clinical guidelines recommend off label standard therapies, including topical corticosteroids (TCS), topical calcineurin inhibitors (TCI), phototherapy (narrowband UVB or excimer devices), and selected off-label systemic regimens.

MATERIALS AND METHODS:

This review summarizes the scientific evidence on approved and guideline-recommended treatments for adult vitiligo, using a PRISMA-based approach. Only English-language articles published between 2000 and 2025 were included. Interventions comprised approved therapies and standard treatments recommended by guidelines. Outcomes evaluated were changes in Facial and Total Vitiligo Area Scoring Index (F-VASI/T-VASI), quality of life, and safety. Risk of bias was assessed using the Risk of Bias 2 (RoB 2) tool for randomized controlled trials (RCTs) and the Risk of Bias in Non-randomized Studies of Interventions (ROBINS-I) for non-randomized studies.

RESULTS:

Ruxolitinib cream demonstrated superior F-VASI responses compared with vehicles in phase II-III RCTs. Evidence supports the efficacy of potent or very potent TCS, TCI, and NB-UVB or targeted 308-nm devices in localized disease.

CONCLUSION:

Systemic regimens show benefits in selected clinical scenarios, although supporting evidence remains heterogeneous. Treatment selection should be individualized based on disease activity, extent, anatomical site, and patient preferences.

31 Dec 2026·ANNALS OF MEDICINE

Efficacy and safety of Ruxolitinib-based combination therapy in the patients with Myelofibrosis (MF): a systematic review and meta-analysis

Review

Author: Li, Yuxin ; Sun, Wanling ; Cao, Yaofang ; Hui, Wuhan ; Tan, Shuai

BACKGROUND:

Myelofibrosis (MF) is a chronic myeloproliferative neoplasm. Although Ruxolitinib, a JAK1/2 inhibitor, remains the cornerstone of MF treatment, it does not reverse disease progression, and resistance frequently emerges. These limitations have prompted investigation into combination therapies targeting pathways beyond the JAK-STAT axis. This meta-analysis aims to evaluate the efficacy and safety of Ruxolitinib-based combination therapies in patients with MF.

METHODS:

We conducted a systematic search of databases for studies published through August 1, 2025. Thirteen distinct Ruxolitinib-based combination regimens were included. Primary efficacy endpoints were ≥35% spleen volume reduction at 24 weeks (SVR35) and ≥50% reduction in total symptom score (TSS50). Safety endpoints focused on the incidence of grade 3/4 thrombocytopenia and anemia. Subgroup analyses were performed based on prior JAK inhibitor exposure and therapeutic mechanism of action.

RESULTS:

A total of 19 studies comprising 1,088 patients were included in the meta-analysis. Among JAK inhibitor-naïve patients, the combination of Ruxolitinib with Selinexor demonstrated the highest efficacy (SVR35: 92%; TSS50: 78%), followed by Ruxolitinib plus BMS-986158 (SVR35: 90%). For patients with prior JAK inhibitor exposure, Ruxolitinib plus Siremadlin (SVR35: 45%) showed notable activity.

CONCLUSION:

For JAK inhibitor-naïve patients, Ruxolitinib-based combination regimens demonstrated satisfactory clinical responses and the potential for meaningful disease control. For patients with prior JAK inhibitor exposure, the addition of combination therapy drugs may further enhance the efficacy. Personalized treatment selection remains essential, as therapeutic efficacy is significantly influenced by prior JAK inhibitor exposure.

31 Dec 2026·Hematology

Distinct clinical, molecular, and treatment response profiles in primary and secondary myelofibrosis: a single-center retrospective study

Article

Author: Liu, Yumei ; Fu, Rong ; Shao, Zonghong ; Wang, Huaquan ; Dong, Xifeng ; Ren, Yue ; Liu, Wenya ; Xing, Limin ; Yang, Liyan ; Liang, Yingao

BACKGROUND:

Myelofibrosis (MF) includes primary myelofibrosis (PMF) and secondary myelofibrosis (SMF) evolving from essential thrombocythemia (ET) or polycythemia vera (PV). The clinical and molecular heterogeneity of MF remains incompletely characterized in real-world cohorts.

METHODS:

We retrospectively analyzed 56 patients with MF treated at a single center, including 33 with PMF and 23 with SMF (ET-MF or PV-MF). Clinical characteristics, laboratory parameters, bone marrow pathology, cytogenetic and molecular findings, treatment strategies, and follow-up outcomes were evaluated.

RESULTS:

PMF patients demonstrated a predominantly cytopenic phenotype, characterized by more severe anemia and lower platelet counts, whereas SMF patients showed a more proliferative profile with higher leukocyte and platelet counts. Bone marrow examination revealed typical megakaryocytic atypia and reticulin fibrosis in both groups, while PMF exhibited more heterogeneous marrow cellularity. Mutational analysis showed that JAK2 was the most frequent driver mutation, followed by CALR and MPL, and approximately one-third of PMF cases were triple-negative. Among additional mutations, ASXL1 was the most common, followed by spliceosome-related genes such as SF3B1 and U2AF1. Patients harboring JAK2 mutations displayed higher hemoglobin levels, red blood cell counts, and neutrophil percentages compared with JAK2-wild type patients. Treatment strategies included supportive care, interferon, hydroxyurea, and ruxolitinib. During follow-up, most patients remained alive, although leukemic transformation occurred in a small proportion of PMF cases.

CONCLUSIONS:

PMF and SMF demonstrate distinct clinical phenotypes despite sharing bone marrow fibrosis as a common endpoint. The mutational landscape highlights the genetic heterogeneity of MF and underscores the importance of integrating clinical, pathological, and molecular information to improve disease characterization and guide individualized management.

127

News (Medical) associated with Ruxolitinib

20 Sep 2026

·www.prnewswire.com

Specialised Therapeutics Expands Partnership with Incyte to Include Ruxolitinib Cream (Opzelura®) in Australia

SINGAPORE, Sept. 20, 2026 /PRNewswire/ -- Independent biopharmaceutical company Specialised Therapeutics (ST) today announced an expansion of its existing partnership with Incyte Biosciences International, an affiliate of Incyte (NASDAQ: INCY), to commercialise, distribute, and register ruxolitinib cream (registered as Opzelura® in the U.S. and European Union) in Australia. Ruxolitinib (1.5%) cream is a novel, topical Janus kinase (JAK) inhibitor.[1] In the U.S., OPZELURA is indicated for the topical treatment of non-segmental vitiligo in adults and pediatric patients 12 years of age and older, as well as for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adult and pediatric patients 2 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.[2] Under the terms of the expanded agreement, Incyte will remain responsible for the development and manufacturing of ruxolitinib cream, while ST will manage regulatory submissions, medical affairs, marketing, and distribution across Australia. ST Chief Executive Officer, Mr Carlo Montagner, welcomed the addition of ruxolitinib cream to ST's portfolio, marking a key expansion into inflammatory dermatology. "Our partnership with Incyte began in 2021, and we are pleased to extend this collaboration into dermatology," said Mr Montagner. "Atopic dermatitis and vitiligo are chronic skin conditions that carry a significant physical and psychosocial burden for patients.[3],[4] Bringing ruxolitinib cream to the Australian market aligns with our ongoing commitment to providing innovative therapies for conditions where substantial unmet medical needs remain." "Our immediate priority will be navigating the local regulatory and reimbursement pathways to ensure eligible Australian patients gain equitable and timely access to this topical treatment," Mr Montagner added. Incyte Head of International, Lee Heeson, noted that the expanded agreement reinforces the strong operational alignment between the two organisations. "We are pleased to expand our partnership with Specialised Therapeutics as we work to make ruxolitinib cream available to eligible patients in Australia," said Lee Heeson, Executive Vice President and Head of Incyte International. "ST's proven experience navigating regulatory, medical and commercial pathways across the region makes them a valued partner as we continue to broaden access to our portfolio globally." ST anticipates progressing regulatory and reimbursement submissions for OPZELURA with Australian healthcare authorities in due course. – ENDS – About Specialised Therapeutics Founded in 2007, Specialised Therapeutics is an independent specialty pharmaceutical company, providing novel therapies and technologies to patients in Australia, New Zealand and across Southeast Asia. Headquartered in Singapore, ST partners with global pharmaceutical, biotech and diagnostic companies to bring novel healthcare opportunities to patients who are impacted by a range of diseases. ST has built a strong track record of success, navigating complex regulatory, reimbursement and commercialisation environments in its diverse regions across multiple therapeutic areas. The ST mission is to provide specialty therapies where there is an unmet need to communities that would otherwise not have ready access to such therapies. The company's broad therapeutic portfolio currently includes novel agents in oncology, haematology, CNS, neurology, endocrinology, ophthalmology and dermatology, although it is not confined to these areas. Additional information can be found at . About Ruxolitinib Cream (OPZELURA) Ruxolitinib cream (OPZELURA) a novel cream formulation of Incyte's selective JAK1/JAK2 inhibitor ruxolitinib, approved by the U.S. FDA for the topical treatment of nonsegmental vitiligo in patients 12 years of age and older, is the first and only treatment for repigmentation approved for use in the United States. OPZELURA is also approved in the U.S. for the topical short-term and non-continuous chronic treatment of mild to moderate AD in non-immunocompromised patients 2 years of age and older whose disease is not adequately controlled with topical prescription therapies, or when those therapies are not advisable. Use of OPZELURA in combination with therapeutic biologics, other JAK inhibitors, or potent immunosuppressants, such as azathioprine or cyclosporine, is not recommended.[2] In Europe, OPZELURA (ruxolitinib) cream 15mg/g is approved for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age and in adult patients with moderate atopic dermatitis (AD) for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate.[5] Incyte has worldwide rights for the development and commercialisation of OPZELURA. To date, more than one million patients globally have been treated with OPZELURA. OPZELURA is a registered trademark of Incyte. References: SOURCE Specialised Therapeutics 21% more press release views with Request a Demo

Drug ApprovalLicense out/in

18 Sep 2026

·www.biospace.com

MaaT Pharma Provides Update on MaaT013 (Xervyteg®) Potential Development Plan Following CHMP Negative Opinion After Re-examination

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a negative opinion on the Company’s application for a Conditional Marketing Authorization (CMA) for MaaT013 (Xervyteg ® ), confirming the trend communicated on September 15, 2026, following the Oral Explanation During the application process, MaaT Pharma proposed conducting a randomized controlled Phase 3 trial versus Best Available Therapy (BAT), named PHOENIX, which would serve the purpose of regulatory submission in the U.S., Europe and other territories Food and Drug Administration (FDA) Type C feedback supports advancement of the pivotal PHOENIX Phase 3 trial which could enable study initiation leading to a potential first patient enrollment in H1 2027, subject to appropriate funding and regulatory clearance LYON, France--(BUSINESS WIRE)-- $MAAT #Cancer --Regulatory News: MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies™ (MET) dedicated to enhancing survival for patients with cancer through immune modulation, today announced that the CHMP of the EMA has maintained its negative opinion on the CMA application for MaaT013, under the brand name Xervyteg ® , for the treatment of acute Graft-versus-Host Disease (aGvHD) in adult patients with gastrointestinal involvement refractory to prior lines of therapy following re-examination. The European Commission is expected to issue its final decision following the CHMP opinion in accordance with the applicable regulatory process 1 . The Company also indicates that future developments of MaaT013 (Xervyteg ® ) will focus on advancing the PHOENIX randomized clinical trial, subject to appropriate financing and regulatory clearance. The Company is actively exploring options to start U.S. focused development plan for MaaT013 (Xervyteg ® ) with a view to enabling potential global registration. The CHMP maintained its view in its formal opinion adopted on September 18, 2026 that the available clinical data package based on single arm trial does not allow sufficient characterization of the benefit-risk pro MaaT013 (Xervyteg ® ). As part of the re-examination process, MaaT Pharma presented plans for PHOENIX, a global randomized controlled Phase 3 trial intended to generate the additional evidence requested by regulators to further characterize the benefit-risk pro MaaT013. MaaT Pharma is advancing the U.S. clinical readiness for PHOENIX, including completion of a feasibility assessment across major clinical trial sites in US and other planned countries. In addition, feedback received following a Type C interaction with the FDA supports advancement of PHOENIX as a registrational Phase 3 trial and provides a framework for finalizing the study protocol and progressing U.S. development activities, including clinical site activation. Subject to appropriate funding and regulatory clearance, PHOENIX is planned to be conducted across the U.S., Europe and sites in other regions and could also support potential future registration submissions, subject to successful execution and positive results. PHOENIX is a randomized, controlled, open-label Phase 3 trial evaluating MaaT013 (Xervyteg ® ) versus pre-specified BAT in patients with corticosteroid- and ruxolitinib-refractory aGvHD. The study is expected to enroll approximately 138 patients randomized 1:1 and will evaluate Day 28 all-organ Overall Response Rate as its primary endpoint, alongside key secondary efficacy and safety endpoints. In this context, the Company is conducting a strategic review of its assets while taking additional cash preservation measures, to further extend its cash horizon to December 2026 (vs November 2026), based on current operational assumptions. About MaaT Pharma MaaT Pharma is a leading, late-stage clinical company focused on developing innovative gut microbiome-driven therapies to modulate the immune system and enhance cancer patient survival. Supported by a talented team committed to making a difference for patients worldwide, the Company was founded in 2014 and is based in Lyon, France. As a pioneer, MaaT Pharma is leading the way in bringing the first microbiome-driven immunomodulator in oncology. Using its proprietary pooling and co-cultivation technologies, MaaT Pharma develops high diversity, standardized drug candidates, aiming at extending life of cancer patients. MaaT Pharma has been listed on Euronext Paris (ticker: MAAT) since 2021. About acute Graft-versus-Host Disease Acute Graft-versus-Host Disease occurs in patients within 100 days of undergoing a stem cell or bone marrow transplant, where the transplanted cells initiate an immune response and attack the transplant recipient’s organs, causing inflammation of the skin, liver and/or gastrointestinal tract and leading to significant morbidity and mortality. GI involvement is associated with severe complications such as profound diarrhea, abdominal pain, intestinal bleeding, and death. These complications are often life-threatening, with increased mortality risk, due to the challenges of managing severe GI inflammation and the associated risks of infection, malnutrition, and organ failure. The standard first-line therapy for treating aGvHD is the use of systemic steroids. If patients do not respond to steroids, they are considered steroid resistant (SR) and other agents can be administered. Currently, ruxolitinib is the standard second-line treatment for steroid-refractory acute graft-versus-host disease. More recently, remestemcel-L (rknd) was approved in December 2024 in the United States, specifically for use in the pediatric population as a second-line treatment. About MaaT013 (Xervyteg ® ) MaaT Pharma’s Microbiome Ecosystem Therapies (MET) are designed to leverage a full microbiome ecosystem to restore balance and maximize clinical benefits for patients with severe, treatment-induced dysbiosis in acute diseases. MaaT013 (Xervyteg ® ) is a full-ecosystem, off-the-shelf, standardized, pooled-donors, enema Microbiome Ecosystem Therapy™ for acute, hospital use. It is characterized by a consistently high diversity and richness of microbial species and the presence of Butycore™ (a group of bacterial species known to produce anti-inflammatory metabolites). Xervyteg ® (MaaT013) aims to restore the symbiotic relationship between the patient’s functional gut microbiome and their immune system to correct the responsiveness and tolerance of immune functions and thus reduce the symptoms of steroid-resistant, gastrointestinal (GI)-aGvHD. MaaT013 (Xervyteg ® ) has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Forward-looking Statements All statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company’s control. These statements may include, without limitation, any statements preceded by, followed by, or including words such as “target,” “believe,” “expect,” “aim”, “intend,” “may,” “anticipate,” “estimate,” “plan,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could” and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company’s control that could cause the Company’s actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements. 1 This decision is issued within 67 days of receipt of EMA’s recommendation: Contacts MaaT Pharma – Investor Relations Eric Soyer Chief Financial Officer +33 4 28 29 14 00 invest@maat-pharma.com MaaT Pharma – Media Relations Pauline Richaud Head of Communication +33 6 14 06 45 92 media@maat-pharma.com

Phase 3Orphan DrugImmunotherapyDrug Approval

15 Sep 2026

·www.biospace.com

MaaT Pharma Receives Negative CHMP Trend Vote for MaaT013 (Xervyteg®) Following Re-Examination for its Conditional Marketing Authorization Application in Europe

MaaT Pharma was informed of a negative trend during the Committee for Medicinal Products for Human Use (CHMP)’s Oral Explanation meeting which took place on September 14, 2026 Formal CHMP opinion is expected on September 18, 2026 Based on the feedback received following the Oral Explanation, the remaining concerns relate primarily to the attribution of clinical benefit and safety in the absence of a Randomized Control Trial The Company will provide further updates following the formal CHMP opinion LYON, France--(BUSINESS WIRE)-- $MAAT --Regulatory News: MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies™ (MET) dedicated to enhancing survival for patients with cancer through immune modulation, today announced that it has been informed by the CHMP of the European Medicines Agency (EMA) of a “negative trend” opinion following the Oral Explanation, as part of the re-examination procedure of its conditional Marketing Authorization Application (MAA) for MaaT013 (Xervyteg ® ) for the treatment of aGvHD, following yesterday’s CHMP oral explanation. "We are deeply disappointed by this outcome. Patients suffering from gastrointestinal-aGvHD continue to face a life-threatening condition with significant unmet medical need and limited treatment options," said Hervé Affagard, Chief Executive Officer and co-founder of MaaT Pharma. "Together with the hematology community, we remain committed to these patients and will evaluate all available options to make this potentially important treatment accessible to patients worldwide." Based on the feedback received post Oral Explanation, the CHMP maintained its view that the available clinical data package, primarily in the absence of a randomized control trial, does not allow sufficient characterization of the benefit/risk of MaaT013 (Xervyteg ® ). The Company will provide additional details following the formal CHMP opinion, which is expected to be communicated on September 18, 2026. The Company will assess the implications of the decision and evaluate all available options and will provide an update to the market as appropriate. About MaaT Pharma MaaT Pharma is a leading, late-stage clinical company focused on developing innovative gut microbiome-driven therapies to modulate the immune system and enhance cancer patient survival. Supported by a talented team committed to making a difference for patients worldwide, the Company was founded in 2014 and is based in Lyon, France. As a pioneer, MaaT Pharma is leading the way in bringing the first microbiome-driven immunomodulator in oncology. Using its proprietary pooling and co-cultivation technologies, MaaT Pharma develops high diversity, standardized drug candidates, aiming at extending life of cancer patients. MaaT Pharma has been listed on Euronext Paris (ticker: MAAT) since 2021. About acute Graft-versus-Host Disease Acute Graft-versus-Host Disease occurs in patients within 100 days of undergoing a stem cell or bone marrow transplant, where the transplanted cells initiate an immune response and attack the transplant recipient’s organs, causing inflammation of the skin, liver and/or gastrointestinal tract and leading to significant morbidity and mortality. GI involvement is associated with severe complications such as profound diarrhea, abdominal pain, intestinal bleeding, and death. These complications are often life-threatening, with increased mortality risk, due to the challenges of managing severe GI inflammation and the associated risks of infection, malnutrition, and organ failure. The standard first-line therapy for treating aGvHD is the use of systemic steroids. If patients do not respond to steroids, they are considered steroid resistant (SR) and other agents can be administered. Currently the only agent approved for treating SR aGvHD after failure of steroid treatment is ruxolitinib, which is currently approved for this indication in USA and has received approval from the European Medicines Agency’s Committee for Human Medicinal Products (CHMP) on March 25, 2022. About MaaT013 (Xervyteg ® ) MaaT Pharma’s Microbiome Ecosystem Therapies (MET) are designed to leverage a full microbiome ecosystem to restore balance and maximize clinical benefits for patients with severe, treatment-induced dysbiosis in acute diseases. MaaT013 (Xervyteg ® ) is a full-ecosystem, off-the-shelf, standardized, pooled-donors, enema Microbiome Ecosystem Therapy™ for acute, hospital use. It is characterized by a consistently high diversity and richness of microbial species and the presence of Butycore™ (a group of bacterial species known to produce anti-inflammatory metabolites). Xervyteg ® (MaaT013) aims to restore the symbiotic relationship between the patient’s functional gut microbiome and their immune system to correct the responsiveness and tolerance of immune functions and thus reduce steroid-resistant, gastrointestinal (GI)-aGvHD. Xervyteg ® (MaaT013) has been granted Orphan Drug Designation by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Forward-looking Statements All statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company’s control. These statements may include, without limitation, any statements preceded by, followed by, or including words such as “target,” “believe,” “expect,” “aim”, “intend,” “may,” “anticipate,” “estimate,” “plan,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could” and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company’s control that could cause the Company’s actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements. Contacts MaaT Pharma – Investor Relations Eric Soyer Chief Financial Officer +33 4 28 29 14 00 invest@maat-pharma.com MaaT Pharma – Media Relations Pauline Richaud Head of Communication +33 6 14 06 45 92 media@maat-pharma.com

Orphan DrugDrug ApprovalClinical StudyImmunotherapyMicrobial therapy

100 Deals associated with Ruxolitinib

External Link

KEGG	Wiki	ATC	Drug Bank
D09959	-	-	-

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
prurigo nodularis	Phase 3	China	Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd.	15 Dec 2025
Pruritus	Phase 3	China	Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd.	15 Dec 2025
Nonsegmental vitiligo	Phase 3	China	Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd.	01 Nov 2024
Acute Myeloid Leukemia	Phase 2	United States	Constellation Pharmaceuticals, Inc.	16 Jul 2014
Acute Myeloid Leukemia	Phase 2	Belgium	Constellation Pharmaceuticals, Inc.	16 Jul 2014
Acute Myeloid Leukemia	Phase 2	Canada	Constellation Pharmaceuticals, Inc.	16 Jul 2014
Acute Myeloid Leukemia	Phase 2	France	Constellation Pharmaceuticals, Inc.	16 Jul 2014
Acute Myeloid Leukemia	Phase 2	Germany	Constellation Pharmaceuticals, Inc.	16 Jul 2014
Acute Myeloid Leukemia	Phase 2	Italy	Constellation Pharmaceuticals, Inc.	16 Jul 2014
Acute Myeloid Leukemia	Phase 2	Netherlands	Constellation Pharmaceuticals, Inc.	16 Jul 2014

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04562389 (SENTRY, Pubmed \| J Clin Oncol)	Phase 3	Myelofibrosis	353	Selinexor plus Ruxolitinib	qxmgnwdumn(ltdmuxrqnb) = iixaahxkhx oageasglwl (dpmtkgszml ) View more	Positive	01 Aug 2026
				Placebo plus Ruxolitinib	qxmgnwdumn(ltdmuxrqnb) = rcvyiforjj oageasglwl (dpmtkgszml ) View more
NCT05998408 (CTgov)	Phase 1/2	Large Granular Lymphocytic Leukemia \| Anemia, Aplastic	13	Ruxolitinib (Cohort 2: Participants With Moderate Aplastic Anemia (MAA))	txgyijzutl = phbharvtee nbyroanipo (ajmovcdawg, vgpwudfpqu - ndtsvwjebt) View more	-	15 Jul 2026
				Ruxolitinib (Cohort 3: Participants With Unilineage Bone Marrow Failure Disorder)	txgyijzutl = mykqxffsrv nbyroanipo (ajmovcdawg, nxyzohcueq - cnbwcspuxh) View more
ESC2026	Not Applicable	Myocarditis	23	Ruxolitinib + Abatacept + Glucocorticoids	jqukignlck(bpmciegxnk) = xvllgbpeef zpbmyyluwk (rfcwxzmwcr ) View more	Positive	19 Jun 2026
EULAR2026	Not Applicable	Giant Cell Arteritis	47	Secukinumab	hhzlpqnawe(yayqmrtnbo) = kzfnielphb kdtlssmoam (xxxjqisifm ) View more	Positive	11 Jun 2026
				Jak inhibitors	ofndnwkugn(mdpsbjvicb) = izxrecxzmi mxsohrdvtv (hvgwibprcl ) View more
NCT04562389 (SENTRY, EHA2026)	Phase 3	Myelofibrosis	353	Selinexor+Ruxolitinib	hburahohyv(lvmejdkskk) = szmlslqnuz rkdkdtxkbw (fwweaulhai ) View more	Positive	02 Jun 2026
				Placebo+Ruxolitinib	hburahohyv(lvmejdkskk) = zzxvlomutl rkdkdtxkbw (fwweaulhai ) View more
ASCO2026	Not Applicable	Myeloproliferative Disorders	62,333	Ruxolitinib	uajsvtrpkq(crjejmqqkk) = xcctcsgdwm kdjzqvnuzw (ovlqbdewkx ) View more	Negative	29 May 2026
				Fedratinib	uajsvtrpkq(crjejmqqkk) = gbguqmeswn kdjzqvnuzw (ovlqbdewkx )
EHA2026	Not Applicable	Myelofibrosis	968	Ruxolitinib	wdywcyyaor(zyyidtsdih) = brjsocrxxy vpwvhlychs (bzycoavlmh ) View more	Positive	12 May 2026
EHA2026	Not Applicable	Myelofibrosis	54	Ruxolitinib	mrncoggotz(ybanonrxiq) = ivzxxptxqj yuuwfrtwns (cvrvhqaiuc ) View more	Positive	12 May 2026
EHA2026	Not Applicable	Polycythemia Vera	12	Ruxolitinib	hjjnhiukkw(othkpizoca) = oowkddqigo tdxtaomrjv (uqkijilvqg )	Positive	12 May 2026
EHA2026	Not Applicable	Myeloproliferative Disorders	97	Ruxolitinib	pfevlczjkb(maikyeuobp) = dfgzimcayb krgdsxcgzl (mkuhzadhil ) View more	Positive	12 May 2026
				Ruxolitinib (post-essential thrombocythaemia MF)	quzqvmbqds(qpbfqsgdzh) = tgylioonfp gfzkurthqm (dpdlertvtn ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis